Leerink Partnrs Has Positive Outlook for BNTC Q3 Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC) – Analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for shares of Benitec Biopharma in a report issued on Monday, March 31st. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of ($0.26) per share for the quarter, up from their prior forecast of ($0.28). The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.22) EPS and FY2026 earnings at ($1.19) EPS.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.19.

A number of other brokerages also recently commented on BNTC. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price target on shares of Benitec Biopharma in a report on Monday, March 24th. Baird R W raised Benitec Biopharma to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Robert W. Baird assumed coverage on Benitec Biopharma in a research report on Friday, December 13th. They set an “outperform” rating and a $30.00 target price on the stock. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $24.43.

Benitec Biopharma Stock Down 5.3 %

Shares of NASDAQ:BNTC opened at $12.32 on Thursday. The firm has a fifty day simple moving average of $12.45 and a two-hundred day simple moving average of $11.26. Benitec Biopharma has a 52 week low of $4.75 and a 52 week high of $16.90. The stock has a market capitalization of $288.92 million, a P/E ratio of -8.16 and a beta of 0.76.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L purchased 900,000 shares of the business’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the acquisition, the director now owns 8,793,245 shares in the company, valued at approximately $114,312,185. This trade represents a 11.40 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BNTC. Ameriprise Financial Inc. raised its holdings in Benitec Biopharma by 138.4% in the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock worth $448,000 after purchasing an additional 20,597 shares in the last quarter. 683 Capital Management LLC purchased a new position in shares of Benitec Biopharma in the 4th quarter worth approximately $452,000. Northern Trust Corp grew its position in shares of Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock worth $482,000 after buying an additional 13,425 shares during the last quarter. MYDA Advisors LLC bought a new position in shares of Benitec Biopharma during the 4th quarter worth approximately $632,000. Finally, Lion Point Capital LP lifted its position in Benitec Biopharma by 59.0% during the fourth quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company’s stock valued at $783,000 after acquiring an additional 23,000 shares during the last quarter. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.